Bordetella pertussis in adult pneumonia patients (1).

To the Editor: Although B. pertussis infection is well-characterized in children, the epidemiology and clinical spectrum of pertussis in adolescents and adults are less well defined. Instances of pneumonia complicating adult pertussis have been reported (1,2), yet the role of B. pertussis in adult pneumonia has not been rigorously evaluated.

This study searched specifically for evidence of B. pertussis infection in 304 adults ([greater than or equal to] 18 years) admitted to Christchurch Hospital (Christchurch, New Zealand) with community-acquired pneumonia from August 1999 to July 2000 (3). Nasopharyngeal samples and paired serum samples from these patients were stored and later tested for B. pertussis DNA and B. pertussis antibodies. Culture for B. pertussis was not performed because B. pertussis was not part of the original pneumonia study protocol.

Nasopharyngeal samples were centrifuged and tested for B. pertussis DNA by using the IS481 hemi-nested polymerase chain reaction (PCR) assay described previously (4). Serum samples taken from the patients during acute and convalescent phases of disease were tested for immunoglobulin (Ig)A and IgG antibodies against B. pertussis whole cell antigens by using enzyme-linked immunosorbent assay (ELISA) (Pan Bio, Queensland, Australia). All positive serum samples were tested for pertussis toxin (PT) IgG antibodies, the most specific serologic marker for recent B. pertussis infection (5). This assay, which uses highly purified PT as antigen, has been described in detail elsewhere (6).

Of the 304 adults, both acute and convalescent phase serum samples were available from 257 patients, only acute phase samples were available from 46 patients, and no samples were available from 1 patient; nasopharyngeal swabs samples were available for testing for 275 patients. Overall, 8 (3%) patients had definite recent B. pertussis infection based on B. pertussis DNA in nasopharyngeal samples (8 patients) or elevated levels of anti-PT IgG antibodies (single sample with an anti-PT IgG level [greater than or equal to] 100 EU/mL, or demonstration of a [greater than or equal to] 4-fold rise in anti-PT IgG level) (5 patients). Eighteen (6%) additional patients had evidence of possible recent B. pertussis infection based on elevated levels of IgA antibody or demonstrated IgG antibody seroconversion to whole cell lysate B. pertussis antigens, but had low levels of anti-PT IgG antibodies. A moderate degree of pertussis existed in the community during the study period, with 4-73 notifications per month in the Christchurch region (population 421,000).

Characteristics of the patients with evidence of recent B. pertussis infection are shown in the Table. Other respiratory pathogens identified from the patients with definite recent B. pertussis infection were Streptococcus pneumoniae (2 patients), Haemophilus influenzae (2 patients), respiratory syncytial virus (1 patient), and influenza A virus (1 patient). Respiratory pathogens identified in the group with possible recent B. pertussis infection were S. pneumoniae (6 patients), H. influenzae (2 patients), respiratory syncytial virus (2 patients), influenza A virus (2 patients), Legionella pneumophila (1 patient), adenovirus (1 patient), and Pseudomonas aeruginosa (1 patient). No patients died, but 2 were admitted to the intensive care unit. No clinical or laboratory variables distinguished patients with recent evidence of pertussis from other patients in the study, although the former group had higher proportion of current or ex-smokers (85% vs. 65%; 95% confidence interval for the difference 5%-35%).

This study is the first to systematically search for evidence of B. pertussis infection in adults with community-acquired pneumonia. We found evidence of recent B. pertussis infection in 3% of adults admitted to the hospital with well-defined pneumonia during a period of increased pertussis activity, and weaker evidence in an additional 6%. In comparison, a community-based study of 122 adults with respiratory tract infections found serologic evidence of B. pertussis infection in 7% of the patients (7). Other studies have reported that pneumonia complicates [approximately equal to] 4% of B. pertussis infections in adults (1,2), with the disease increasing with age (1).

B. pertussis infection can be difficult to diagnose, especially if symptoms have been present for many days, and we may have underestimated the number of patients with recent pertussis. However, the combination of PCR and serologic testing is one of the most sensitive approaches for diagnosing pertussis in adolescents and adults (5). The nasopharyngeal samples may not have been optimal for PCR testing because they were placed in viral transport media and had already been processed for viral studies. Although the viral transport media was not inhibitory to the PCR, the amount of cellular material may have decreased after this processing.

Our findings indicate that a small proportion of adults admitted to the hospital with pneumonia had evidence of recent B. pertussis infection. In these persons, whether B. pertussis is a primary or secondary pathogen or an innocent bystander is not clear. Further work is needed to clarify the precise role of B. pertussis in developing adult pneumonia, the risk factors for B. pertussis--associated pneumonia, and the value of specific B. pertussis therapy in this setting. These data will also help inform about the role of pertussis vaccination in adults.

Table. Characteristics of adults with pneumonia and evidence of
recent Bordetella pertussis infection

                             Definite evidence   Possible evidence
                                 of recent           of recent
                               B. pertussis        B. pertussis
                                 infection           infection
                                  (n = 8)            (n = 18)

Characteristics

Median age (range)             68 (37-86) y        71 (34-95) y
Male:female                         4:4                13:5
Current or ex-smokers             6 (75%)            16 (89%)
Median (range) duration of     8.5 (1-21) d        3.5 (1-30) d
  symptoms at admission
Presence of cough                8 (100%)            15 (83%)
Sputum production                 6 (75%)             7 (39%)
Other respiratory tract           6 (75%)            11 (61%)
  pathogens identified

Acknowledgments

We thank Marita Smit, Alvin Chua, and staff from the Microbiology Unit, Canterbury Health Laboratories; members of the Christchurch Community-Acquired Pneumonia Study Group; Nita Doshi and John Duncan; and Pan Bio for providing antibody assays.

Financial support was provided by a Canterbury Medical Research Foundation project grant.

(1) Presented at the Community Acquired Pneumonia Conference, Deerhurst Resort, Ontario, Canada, September 10-12, 2003.

References

(1.) De Serres G, Shadmani R, Duval B, Boulianne N, Dery P, Douville Fradet M, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis. 2000;182:174-9.

(2.) Postels-Multani S, Schmitt HJ, Wirsing von Konig CH, Bock HL, Bogaerts H. Symptoms and complications of pertussis in adults. Infection. 1995;23:139-42.

(3.) Laing R, Slater W, Coles C, Chambers S, Frampton C, Jackson R, et al. Community-acquired pneumonia in Christchurch and Waikato 1999-2000: microbiology and epidemiology. NZ Med J. 2001;114:488 92.

(4.) Anderson TP, Beynon KA, Murdoch DR. Comparison of real-time PCR and conventional nested PCR for the detection of Bordetella pertussis in nasopharyngeal samples. Clin Microbiol Infect. 2003;9:746-9.

(5.) Wirsing von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis. 2002;2:744-50.

(6.) Giammanco A, Chiarini A, Maple PAC, Andrews N, Pebody R, Gay N, et al. European sero-epidemiology network: standardisation of the assay results for pertussis. Vaccine. 2003;22:112-20.

(7.) Lieberman D, Shvartzman P, Lieberman D, Ben Yaakov M, Lazarovich Z, Hoffman S, et al. Etiology of respiratory tract infection in adults in a general practice setting. Eur J Clin Microbiol Infect Dis. 1998;17:685-9.

Kirsten A. Beynon, * Sheryl A. Young, * Richard T.R. Laing, ([dagger]) Timothy G. Harrison, ([double dagger]) Trevor P. Anderson, * and David R. Murdoch * ([dagger])

* Canterbury Health Laboratories, Christchurch, New Zealand; ([dagger]) Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand; and ([double dagger]) Health Protection Agency, London, United Kingdom

Address for correspondence: David R. Murdoch, Microbiology Unit, Canterbury Health Laboratories, P.O. Box 151, Christchurch, New Zealand; fax: [phone]; email: [e-mail]